nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—TNK1—uterine cervix—vulva cancer	0.0335	0.0335	CbGeAlD
Erlotinib—TNK1—urethra—vulva cancer	0.0308	0.0308	CbGeAlD
Erlotinib—TNK1—mammalian vulva—vulva cancer	0.0293	0.0293	CbGeAlD
Erlotinib—EGFR—uterine cervix—vulva cancer	0.0268	0.0268	CbGeAlD
Erlotinib—PIP4K2C—uterine cervix—vulva cancer	0.026	0.026	CbGeAlD
Erlotinib—ULK3—uterine cervix—vulva cancer	0.0248	0.0248	CbGeAlD
Erlotinib—CYP1A1—skin epidermis—vulva cancer	0.0246	0.0246	CbGeAlD
Erlotinib—PIP4K2C—urethra—vulva cancer	0.0239	0.0239	CbGeAlD
Erlotinib—EGFR—mammalian vulva—vulva cancer	0.0235	0.0235	CbGeAlD
Erlotinib—MKNK1—uterine cervix—vulva cancer	0.0234	0.0234	CbGeAlD
Erlotinib—ULK3—urethra—vulva cancer	0.0228	0.0228	CbGeAlD
Erlotinib—PIP4K2C—mammalian vulva—vulva cancer	0.0227	0.0227	CbGeAlD
Erlotinib—TNK1—vagina—vulva cancer	0.0227	0.0227	CbGeAlD
Erlotinib—SLK—uterine cervix—vulva cancer	0.0221	0.0221	CbGeAlD
Erlotinib—ULK3—mammalian vulva—vulva cancer	0.0217	0.0217	CbGeAlD
Erlotinib—MKNK1—urethra—vulva cancer	0.0215	0.0215	CbGeAlD
Erlotinib—MKNK1—mammalian vulva—vulva cancer	0.0204	0.0204	CbGeAlD
Erlotinib—SLK—urethra—vulva cancer	0.0203	0.0203	CbGeAlD
Erlotinib—LTK—lymph node—vulva cancer	0.02	0.02	CbGeAlD
Erlotinib—SLK—mammalian vulva—vulva cancer	0.0194	0.0194	CbGeAlD
Erlotinib—STK10—uterine cervix—vulva cancer	0.0192	0.0192	CbGeAlD
Erlotinib—ABL2—vagina—vulva cancer	0.0186	0.0186	CbGeAlD
Erlotinib—PIP4K2C—vagina—vulva cancer	0.0176	0.0176	CbGeAlD
Erlotinib—AURKC—lymph node—vulva cancer	0.0173	0.0173	CbGeAlD
Erlotinib—MAP2K5—uterine cervix—vulva cancer	0.0172	0.0172	CbGeAlD
Erlotinib—STK10—mammalian vulva—vulva cancer	0.0168	0.0168	CbGeAlD
Erlotinib—ULK3—vagina—vulva cancer	0.0168	0.0168	CbGeAlD
Erlotinib—JAK3—lymph node—vulva cancer	0.016	0.016	CbGeAlD
Erlotinib—MKNK1—vagina—vulva cancer	0.0158	0.0158	CbGeAlD
Erlotinib—MAP2K5—urethra—vulva cancer	0.0158	0.0158	CbGeAlD
Erlotinib—MAP2K5—mammalian vulva—vulva cancer	0.015	0.015	CbGeAlD
Erlotinib—SLK—vagina—vulva cancer	0.015	0.015	CbGeAlD
Erlotinib—TNK1—lymph node—vulva cancer	0.0147	0.0147	CbGeAlD
Erlotinib—ABL1—uterine cervix—vulva cancer	0.0133	0.0133	CbGeAlD
Erlotinib—STK10—vagina—vulva cancer	0.013	0.013	CbGeAlD
Erlotinib—FLT3—lymph node—vulva cancer	0.0126	0.0126	CbGeAlD
Erlotinib—ABL1—urethra—vulva cancer	0.0122	0.0122	CbGeAlD
Erlotinib—ABL2—lymph node—vulva cancer	0.012	0.012	CbGeAlD
Erlotinib—EGFR—lymph node—vulva cancer	0.0118	0.0118	CbGeAlD
Erlotinib—MAP2K5—vagina—vulva cancer	0.0116	0.0116	CbGeAlD
Erlotinib—ABL1—mammalian vulva—vulva cancer	0.0116	0.0116	CbGeAlD
Erlotinib—PIP4K2C—lymph node—vulva cancer	0.0114	0.0114	CbGeAlD
Erlotinib—ULK3—lymph node—vulva cancer	0.0109	0.0109	CbGeAlD
Erlotinib—MKNK1—lymph node—vulva cancer	0.0102	0.0102	CbGeAlD
Erlotinib—SLK—lymph node—vulva cancer	0.0097	0.0097	CbGeAlD
Erlotinib—ABL1—vagina—vulva cancer	0.00898	0.00898	CbGeAlD
Erlotinib—STK10—lymph node—vulva cancer	0.00843	0.00843	CbGeAlD
Erlotinib—ABCG2—uterine cervix—vulva cancer	0.00836	0.00836	CbGeAlD
Erlotinib—CYP1A1—epithelium—vulva cancer	0.008	0.008	CbGeAlD
Erlotinib—CYP1A1—uterine cervix—vulva cancer	0.00793	0.00793	CbGeAlD
Erlotinib—CYP3A5—uterine cervix—vulva cancer	0.00776	0.00776	CbGeAlD
Erlotinib—ABCG2—urethra—vulva cancer	0.00768	0.00768	CbGeAlD
Erlotinib—MAP2K5—lymph node—vulva cancer	0.00753	0.00753	CbGeAlD
Erlotinib—ABCG2—mammalian vulva—vulva cancer	0.00731	0.00731	CbGeAlD
Erlotinib—CYP1A1—urethra—vulva cancer	0.00729	0.00729	CbGeAlD
Erlotinib—CYP1A1—mammalian vulva—vulva cancer	0.00694	0.00694	CbGeAlD
Erlotinib—ORM1—lymph node—vulva cancer	0.00611	0.00611	CbGeAlD
Erlotinib—SLCO2B1—lymph node—vulva cancer	0.00586	0.00586	CbGeAlD
Erlotinib—CYP2C8—vagina—vulva cancer	0.00582	0.00582	CbGeAlD
Erlotinib—ABL1—lymph node—vulva cancer	0.00581	0.00581	CbGeAlD
Erlotinib—ABCG2—vagina—vulva cancer	0.00566	0.00566	CbGeAlD
Erlotinib—CYP1A1—vagina—vulva cancer	0.00538	0.00538	CbGeAlD
Erlotinib—ALB—lymph node—vulva cancer	0.00536	0.00536	CbGeAlD
Erlotinib—CYP3A5—vagina—vulva cancer	0.00526	0.00526	CbGeAlD
Erlotinib—CYP1B1—lymph node—vulva cancer	0.00492	0.00492	CbGeAlD
Erlotinib—ABCB1—epithelium—vulva cancer	0.00416	0.00416	CbGeAlD
Erlotinib—ABCB1—uterine cervix—vulva cancer	0.00412	0.00412	CbGeAlD
Erlotinib—ABCB1—urethra—vulva cancer	0.00379	0.00379	CbGeAlD
Erlotinib—ABCG2—lymph node—vulva cancer	0.00366	0.00366	CbGeAlD
Erlotinib—ABCB1—mammalian vulva—vulva cancer	0.00361	0.00361	CbGeAlD
Erlotinib—CYP1A1—lymph node—vulva cancer	0.00348	0.00348	CbGeAlD
Erlotinib—ABCB1—vagina—vulva cancer	0.00279	0.00279	CbGeAlD
Erlotinib—ABCB1—lymph node—vulva cancer	0.00181	0.00181	CbGeAlD
